This company has been marked as potentially delisted and may not be actively trading. Seelos Therapeutics (SEEL) News Today Add Compare Share Share Headlines Stock AnalysisHeadlinesOwnershipTrendsBuy This Stock SEEL Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Seelos Therapeutics Stock Price HistoryJune 4, 2025 | investing.comPsychedelic stocks rise as FDA chief’s comments seen favorable to industryMay 20, 2025 | msn.comPsychedelic drug developer Lykos could get lifeline from former Tesla board memberJanuary 10, 2025 | msn.comSeelos Therapeutics, Inc. (SEELQ)December 11, 2024 | finance.yahoo.comSeelos Therapeutics Inc SEELQNovember 27, 2024 | morningstar.comMSeelos Announces Second Postponement of its Annual Meeting of StockholdersOctober 24, 2024 | prnewswire.comSeelos Therapeutics Delisted From Nasdaq, Will Transition To OTC MarketOctober 16, 2024 | benzinga.comSeelos gets Nasdaq delisting noticeOctober 15, 2024 | msn.comSeelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter MarketOctober 15, 2024 | prnewswire.comSeelos Announces Postponement of its Annual Meeting of StockholdersSeptember 26, 2024 | prnewswire.comSeelos Therapeutics, Inc.: Seelos Therapeutics Announces 1-for-16 Reverse Stock SplitSeptember 25, 2024 | finanznachrichten.deSeelos Therapeutics to execute 1-for-16 reverse stock splitSeptember 25, 2024 | msn.comSeelos Therapeutics Announces 1-for-16 Reverse Stock SplitSeptember 25, 2024 | prnewswire.comSeelos Therapeutics (NASDAQ:SEEL) Stock Quotes, Forecast and News SummarySeptember 25, 2024 | benzinga.comSeelos Therapeutics (NASDAQ:SEEL) Stock, Short Interest ReportSeptember 25, 2024 | benzinga.comWhat's Going On With Seelos Therapeutics Stock Tuesday?September 24, 2024 | msn.comSeelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSDSeptember 24, 2024 | prnewswire.comSeelos Therapeutics files to sell 1.95M shares of common stock for holdersAugust 17, 2024 | msn.comSEEL Stock Earnings: Seelos Therapeutics Beats Revenue for Q2 2024August 16, 2024 | investorplace.com3 Next-Gen Drug Stocks Exploring Psychedelic FrontiersJuly 8, 2024 | investorplace.comSeelos Therapeutics announces pricing of about $1M registered direct offering & concurrent private placementMay 17, 2024 | msn.comSeelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesMay 16, 2024 | prnewswire.comSEEL Stock Earnings: Seelos Therapeutics Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | investorplace.comSeelos Therapeutics Announces 1-for-8 Reverse Stock SplitMay 14, 2024 | prnewswire.comSEEL Seelos Therapeutics, Inc.May 4, 2024 | seekingalpha.comSeelos Therapeutics to Cut Workforce by 33%, Reduce Working HoursMay 3, 2024 | marketwatch.comSeelos Therapeutics Appoints Richard Pascoe As Chairman Of The BoardApril 29, 2024 | markets.businessinsider.comSeelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and CollaborationsApril 29, 2024 | prnewswire.comSEEL Stock Earnings: Seelos Therapeutics Beats EPS for Q4 2023March 22, 2024 | investorplace.comOptimistic Buy Rating for Seelos Therapeutics Amid Promising Drug Trial ResultsMarch 20, 2024 | markets.businessinsider.comSeelos: Phase 2/3 HEALEY ALS Trial Fails To Meet Statistical Significance In EndpointsMarch 19, 2024 | markets.businessinsider.comSeelos Therapeutics Shares Drop 47% After SLS-005 Trial Misses Primary EndpointsMarch 19, 2024 | marketwatch.comNasdaq Down 100 Points; US Housing Starts Surge In FebruaryMarch 19, 2024 | markets.businessinsider.comCNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's WhyMarch 19, 2024 | msn.comSeelos says ALS treatment fails in mid-stage studyMarch 19, 2024 | reuters.comUPDATE 2-Seelos Therapeutics' ALS treatment fails mid-stage studyMarch 19, 2024 | finance.yahoo.comSeelos falls as lead drug fails in ALS trialMarch 19, 2024 | msn.comSeelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)March 19, 2024 | prnewswire.comSeelos Therapeutics Inc.February 9, 2024 | thestreet.comSeelos Therapeutics, Inc. (SEEL)February 1, 2024 | ca.finance.yahoo.comSeelos Therapeutics Issues Common Warrants to InvestorsJanuary 31, 2024 | msn.comSeelos Therapeutics Strikes $4M Direct Offering DealJanuary 31, 2024 | msn.comSeelos Therapeutics Announces $4 Mln Direct Offering And Private Placement Of SharesJanuary 26, 2024 | markets.businessinsider.comSeelos Therapeutics Shares Hit 52-Week Low After Direct Offering PricesJanuary 26, 2024 | marketwatch.comSeelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesJanuary 26, 2024 | finance.yahoo.comSeelos Therapeutics Says Received Minutes From End Of Phase II Meeting With FDAJanuary 22, 2024 | markets.businessinsider.comSeelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002January 22, 2024 | finance.yahoo.comTherapy’s New Frontier: 3 Psychedelic Stocks for the Mental Health RevolutionJanuary 17, 2024 | finance.yahoo.comSeelos Therapeutics, Inc. (SEEL) stock forecast and price targetJanuary 16, 2024 | finance.yahoo.comSeelos Therapeutics Inc SEELJanuary 5, 2024 | morningstar.comM Get Seelos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SEEL Media Mentions By Week SEEL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SEEL News Sentiment▼0.000.97▲Average Medical News Sentiment SEEL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SEEL Articles This Week▼00▲SEEL Articles Average Week Get the Latest News and Ratings for SEEL and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Seelos Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AIMDW News Today BCTXW News Today ENGNW News Today FBIOP News Today GOVXW News Today INDV News Today INCR News Today JSPRW News Today LEXXW News Today NERV News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SEEL) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seelos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seelos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access